Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study

Objective Through predictable pharmacokinetics—including a convenient fixed-dose regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in anticoagulation for various indications. However, the association between higher body weight and the risk of adverse consequences is not well studied among DOAC users. We aim to explore the association of body weight and adverse clinical outcomes in DOAC users. Methods A total of 97,413 anonymised DOAC users in a tertiary care setting were identified following structured queries on the electronic health records (EHRs) to extract the feature-rich anonymised dataset. The prepared dataset was analysed, and the features identified with machine learning (ML) informed the adjustments of covariates in the multivariate regression analysis to examine the association. Kaplan–Meier analysis was performed to evaluate the mortality benefits of DOACs. Results Among DOAC users, the odds of adverse clinical outcomes, such as clinically relevant non-major bleeding (CRNMB), ischaemic stroke, all-cause mortality, and prolonged hospital stay, were lower in patients with overweight, obesity, or morbid obesity than in patients with normal body weight. The odds of ischaemic stroke (OR 0.42, 95% CI: 0.36–0.88, p = 0.001) and all-cause mortality (OR 0.87, 95% CI: 0.81–0.95, p = 0.001) were lower in patients with morbid obesity than in patients with normal body weight. In the Kaplan–Meier analysis, apixaban was associated with a significantly lower rate of mortality overall and in obesity and overweight subgroups than other DOACs (p < 0.001). However, rivaroxaban performed better than apixaban in the morbid obesity subgroup (p < 0.001). Conclusion This study shows the positive effects of DOAC therapy on clinical outcomes, particularly in patients with high body weight. However, this still needs validation by further studies particularly among patients with morbid obesity..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:80
Enthalten in:	European journal of clinical pharmacology - 80(2023), 1 vom: 18. Nov., Seite 163-173

Sprache:	Englisch

Beteiligte Personen:	Nwanosike, Ezekwesiri Michael [VerfasserIn] Merchant, Hamid A. [VerfasserIn] Sunter, Wendy [VerfasserIn] Ansari, Muhammad Ayub [VerfasserIn] Conway, Barbara R. [VerfasserIn] Hasan, Syed Shahzad [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	Direct oral anticoagulants Electronic health records England Machine learning Mortality Obesity

Anmerkungen:	© The Author(s) 2023

doi:	10.1007/s00228-023-03593-2

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	SPR054332567